Abstract 1498P
Background
Acute myeloid leukemia (AML) is a fatal cancer in patients over 65 years old, with a five-year relative survival rate of 10.8%. There is no literature regarding specific determinants of palliative care (PC) utilization in this population. We studied trends and determinants in PC utilization among hospitalized patients using the National Inpatient Sample (NIS).
Methods
This is a retrospective study using NIS data from 2016 to 2020. We included patients aged 65 years or older who were admitted with AML. We identified patients who had an encounter with PC during their hospitalization. The cohort was divided between patients with an encounter with PC and those without. Baseline characteristics were identified and compared between the two groups. Total charges (TC) during hospitalization were measured as an outcome, and then multivariate logistic regression analysis was performed to adjust for confounders.
Results
There were 44,375 patients over 65 years old admitted with AML. Of those, 22% had an encounter with PC. Baseline characteristics and differences between those in which PC was consulted and those in which they were not consulted are depicted in the table. Significant differences were observed in patients who had an encounter with PC, such as higher utilization in the White race (78% vs. 75%). They had higher rates of Heart Failure (HF) (23% vs 17%, p<0.001), acute kidney injury (AKI) (44% vs. 30%, p<0.001), and chronic kidney disease (CKD) (15% vs 12%, p 0.0018) than patients who did not have an encounter with PC. Type of insurance and hospital bed size were not significantly associated with PC utilization. Significantly, PC was consulted less in hospitals in the south region. While adjusting for other confounders, in the multivariate regression analysis, encounters with PC were associated with a decrease in TC during hospitalization of $ 49,047 (p<0.001).
Conclusions
Overall, PC utilization was low. It was reduced in hospitals located in the south region of the USA. It was higher in patients of the White Race and in patients with HF, AKI, and CKD and was associated with decreased cost burden. Our results highlight the need for early palliative care involvement in patients with AML in hospital settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10